Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
Beta Bionics (NASDAQ: BBNX), a leader in advanced diabetes management solutions, has scheduled the release of its Q4 and full year 2024 financial results for March 25, 2025, after market close.
The company will host a conference call and webcast at 4:30 PM ET (1:30 PM PT) on the same day to discuss the financial performance. Investors can access the webcast through the company's investor relations website, and a replay will be available afterward.
Beta Bionics (NASDAQ: BBNX), un leader nelle soluzioni avanzate per la gestione del diabete, ha programmato la pubblicazione dei suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 25 marzo 2025, dopo la chiusura del mercato.
L'azienda organizzerà una teleconferenza e una diretta web alle 4:30 PM ET (1:30 PM PT) lo stesso giorno per discutere le performance finanziarie. Gli investitori possono accedere alla diretta web tramite il sito web delle relazioni con gli investitori dell'azienda, e una registrazione sarà disponibile successivamente.
Beta Bionics (NASDAQ: BBNX), un líder en soluciones avanzadas para la gestión de la diabetes, ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 25 de marzo de 2025, después del cierre del mercado.
La compañía llevará a cabo una conferencia telefónica y una transmisión en vivo a las 4:30 PM ET (1:30 PM PT) el mismo día para discutir el desempeño financiero. Los inversores pueden acceder a la transmisión en vivo a través del sitio web de relaciones con inversores de la empresa, y una repetición estará disponible posteriormente.
Beta Bionics (NASDAQ: BBNX), 고급 당뇨병 관리 솔루션의 선두주자는 2024년 4분기 및 연간 재무 결과를 2025년 3월 25일 시장 종료 후 발표할 예정입니다.
회사는 같은 날 오후 4시 30분 ET (오후 1시 30분 PT)에 재무 실적을 논의하기 위한 전화 회의 및 웹캐스트를 개최할 것입니다. 투자자들은 회사의 투자자 관계 웹사이트를 통해 웹캐스트에 접근할 수 있으며, 이후에 재생이 가능할 것입니다.
Beta Bionics (NASDAQ: BBNX), un leader dans les solutions avancées de gestion du diabète, a programmé la publication de ses résultats financiers du quatrième trimestre et de l'année entière 2024 pour le 25 mars 2025, après la fermeture du marché.
La société organisera une conférence téléphonique et un webinaire à 16h30 ET (13h30 PT) le même jour pour discuter de la performance financière. Les investisseurs peuvent accéder au webinaire via le site web des relations investisseurs de l'entreprise, et une rediffusion sera disponible par la suite.
Beta Bionics (NASDAQ: BBNX), ein führendes Unternehmen im Bereich fortschrittlicher Diabetesmanagement-Lösungen, hat die Veröffentlichung seiner Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 25. März 2025 nach Börsenschluss angesetzt.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET (13:30 Uhr PT) eine Telefonkonferenz und einen Webcast abhalten, um die finanzielle Leistung zu besprechen. Anleger können über die Investor-Relations-Website des Unternehmens auf den Webcast zugreifen, und eine Aufzeichnung wird anschließend verfügbar sein.
- None.
- None.
IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s fourth quarter and full year 2024 performance.
The link to the webcast will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following link, which will provide you with dial-in details and a personal pin: https://register-conf.media-server.com/register/BI8be51a4e688845529dd55d442f427c91.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Karen Hynes
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
FAQ
When will Beta Bionics (BBNX) release its Q4 2024 earnings?
What time is the BBNX Q4 2024 earnings call?
How can investors access Beta Bionics (BBNX) Q4 2024 earnings call?
Will there be a replay available for BBNX's Q4 2024 earnings call?
